Psychemedics

PMDI · OTC

Price unavailable right now.

No price history for this range.

About PMDI

Psychemedics Corp. engages in the provision of drug testing services through the analysis of hair samples. The company is headquartered in Acton, Massachusetts and currently employs 101 full-time employees. The firm provides testing services for the detection of drugs of abuse through the analysis of hair samples. Its testing methods utilize a patented technology that digests the hair and releases drugs trapped in the hair without destroying the drugs. The firm customizes its enzyme immunoassay (EIA) procedures to drug test hair samples. The company provides screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, phenylcyclohexyl piperidine (PCP), amphetamines (including ecstasy, eve, and Adderall), opiates (including heroin, hydrocodone, hydromorphone, oxycodone and codeine), synthetic cannabinoids (including K2, Spice, Blaze), benzodiazepines (Xanax, Valium, and Ativan), nicotine, Fentanyl, and alcohol. The firm markets its corporate drug testing services through its own sales force, distributors, and partners. The company markets its home drug testing service, PDT-90, through the Internet.

Employees
101
Headquarters
Acton, Massachusetts
Listed
Jan 22, 1987
Sector
Health Care
Industry
Health Care Providers & Services

PMDI key statistics

This section is temporarily unavailable. Refresh to try again.

PMDI earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 106.1% on average.

  1. Q2 FY13: reported $0.20 per share against an estimate of $0.1938
  2. Q3 FY13: reported $0.20 per share against an estimate of $0.204
  3. Q4 FY13: reported $0.16 per share against an estimate of $0.1224
  4. Q1 FY14: reported $0.14 per share against an estimate of $0.1224
  5. Q2 FY14: reported $0.16 per share against an estimate of $0.0306
  6. Q3 FY14: reported $0.12 per share against an estimate of $0.1224
  7. Q4 FY14: reported $0.13 per share against an estimate of $0.0816
  8. Q3 FY23: reported -$0.36 per share against an estimate of $0.00

Similar companies

Companies in the same industry as Psychemedics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.